Venus Remedies aims to achieve top-line of Rs 1000 crore by FY18

24 Sep 2014 Evaluate

Venus Remedies is aiming to achieve a top-line of Rs 1000 crore by FY18 following several new drug launches and increased marketing efforts. The company registered a turnover of Rs 525 crore in FY14. The company has invested around Rs 500 crore in R&D over the last 10 years and received 100 plus patents, 70 trademarks, 9 copyrights and 120 research publications in peer reviewed journals for its R&D based products across the globe. Further, the company has 25 innovative products in pipeline and commercialised 15 products in domestic and international markets.

Following the GMP certification by European and other regulated markets for its manufacturing plants, the company has been able to make international tie-ups for its research products with some of the best pharmaceutical companies of the world.

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.

Venus Remedies Share Price

772.15 13.25 (1.75%)
19-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.10
Dr. Reddys Lab 1278.90
Cipla 1517.00
Zydus Lifesciences 919.85
Lupin 2125.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×